Results 201 to 210 of about 113,188 (264)

Pancreatic cancer induces B cell lineage plasticity via Pax5 inhibition to sustain immunosuppression. [PDF]

Cell Death Discov
Kassem A, Naser Al Deen N, Yifeng S, Fang C, Mayer L, Zhang L, Kunath P, Wirth T, Knippschild U, Rahbari M, Heikenwälder M, Kong B, Brunner C, Weber ANR, Rahbari N, Abdelrasoul H.   +15 more
europepmc   +1 more source

Protein Corona‐Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia

Allergy, EarlyView.
Cuishuang Dong, Xu Zhang, Haoyue Wang, Jiajing Cui, Shuai Han, Yibo Wang, Huanying Zhao, Yang Song, Yuan Zhang, Xiaobo Li   +9 more
wiley   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, EarlyView.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19⁺ B-cell monitoring. [PDF]

CEN Case Rep
Kyoda N, Ago R, Masuzawa N, Yanamoto M, Aizawa M, Masaki T.   +5 more
europepmc   +1 more source

Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma. [PDF]

J Med Cases
Yu TC, Chou WC.
europepmc   +1 more source

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy. [PDF]

Front Immunol
Masuda Y, Kato J, Konishi T, Honda T, Maruta M, Kawasaki N, Matsumoto M, Oka K, Mori K, Nabe S, Miyazaki Y, Matsubara E, Urata S, Kinnami S, Doi Y, Takasuka Y, Yamanouchi J, Ochi T, Takenaka K.   +18 more
europepmc   +1 more source

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm. [PDF]

Cureus
Bansil S, Lai SY, Lo AE, Dietz R, Reed JP.   +4 more
europepmc   +1 more source

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research. [PDF]

Curr Treat Options Oncol
Alipourfard I, Shafaghat Z, Saharkhiz S, Farani MR, Bakhtiyari S.   +4 more
europepmc   +1 more source

Breakthroughs and challenges of CAR-T cell therapy in treating hematologic malignancies of the central nervous system. [PDF]

Blood Sci
Li X, Da H, Zhao J, Yan Y, Wei J, Tian W.   +5 more
europepmc   +1 more source

Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials

British Journal of Haematology, EarlyView.
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Areti Voulomenou, Panagiotis Malandrakis, Efstathios Kastritis, Maria Gavriatopoulou, Meletios‐Athanasios Dimopoulos, Evangelos Terpos   +7 more
wiley   +1 more source